Peter Farrell is founder and chairman of the board of ResMed and has been a director and chairman of the board since its inception in June 1989. He served as chief executive officer from July 1990 until December 2007 and from February 2011 until March 2013. From March 2013 through December 2013, he served as executive chairman, and in January 2014 he became non-executive chairman.
From July 1984 to June 1989, Dr. Farrell served as vice president, research and development at various subsidiaries of Baxter Healthcare, and from August 1985 to June 1989, he also served as managing director of the Baxter Center for Medical Research. From January 1978 to December 1989, he was foundation director of the Graduate School for Biomedical Engineering at the University of New South Wales [UNSW] where he currently serves as a visiting professor and as chairman of the UNSW Centre for Innovation and Entrepreneurship.
Dr. Farrell also serves on several faculty Advisory Boards at UCSD: the Rady Business School, the Jacobs Engineering School and Health Sciences. He also serves on the Visiting Committee of the Health Sciences & Technology Program at MIT. He holds a B.E. in chemical engineering with honors from the University of Sydney, an S.M. in chemical engineering from the Massachusetts Institute of Technology, a Ph.D. in chemical and biomedical engineering from the University of Washington, Seattle and a D.Sc. from the University of New South Wales for research contributions relating to treatment with the artificial kidney.
Dr. Farrell was named 1998 San Diego Entrepreneur of the Year for Health Sciences, Australian Entrepreneur of the Year in 2001 and US National Entrepreneur of the Year for 2005 in Health Sciences. In July 2010, he was named chairman of the Executive Council of the Harvard Medical School Division of Sleep Medicine and served in that capacity until May 2013. In 2012, he joined the Board of Trustees of the Scripps Research Institute. In addition to ResMed, Dr. Farrell is a director of NuVasive, Inc., a Nasdaq-listed company which develops and markets products for the surgical treatment of spine disorders and is non-executive chair of QRxPharma, a clinical-stage specialty pharmaceutical company listed on the ASX. He is a Fellow or Honorary Fellow of several professional bodies, including the Australian Academy of Technological Sciences and Engineering, and is active in philanthropy primarily through the Farrell Family Foundation. Dr. Farrell was president of the Board of Trustees of the Museum of Contemporary Arts, San Diego (2009-2011). In 2011, Dr. Farrell was named a Gordon Fellow by UCSD's Jacobs School of Engineering and in 2012 was admitted as a member of the National Academy of Engineering.
Source: ResMed website
Interviewed by David Caruso, PhD